Abstract
Since cloning and characterization of the sodium iodide symporter (NIS) gene, several investigators explored the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. NIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro and in vivo in several non-thyroidal cancer cell lines. Following PSA promoter-mediated NIS gene delivery we were able to demonstrate prostate-specific iodide accumulation in prostate cancer cells that was high enough to elicit a therapeutic response of 131-I in vitro and in vivo. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for non-thyroidal cancers, in particular prostate cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 56-59 |
| Number of pages | 4 |
| Journal | Experimental and Clinical Endocrinology and Diabetes |
| Volume | 109 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2001 |
Fingerprint
Keywords
- Gene therapy
- Prostate cancer
- Sodium/iodide symporter (NIS)
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
Approaches to gene therapy with sodium/iodide symporter. / Spitzweg, C.; Morris, J. C.
In: Experimental and Clinical Endocrinology and Diabetes, Vol. 109, No. 1, 2001, p. 56-59.Research output: Contribution to journal › Short survey
}
TY - JOUR
T1 - Approaches to gene therapy with sodium/iodide symporter
AU - Spitzweg, C.
AU - Morris, J. C.
PY - 2001
Y1 - 2001
N2 - Since cloning and characterization of the sodium iodide symporter (NIS) gene, several investigators explored the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. NIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro and in vivo in several non-thyroidal cancer cell lines. Following PSA promoter-mediated NIS gene delivery we were able to demonstrate prostate-specific iodide accumulation in prostate cancer cells that was high enough to elicit a therapeutic response of 131-I in vitro and in vivo. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for non-thyroidal cancers, in particular prostate cancer.
AB - Since cloning and characterization of the sodium iodide symporter (NIS) gene, several investigators explored the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. NIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro and in vivo in several non-thyroidal cancer cell lines. Following PSA promoter-mediated NIS gene delivery we were able to demonstrate prostate-specific iodide accumulation in prostate cancer cells that was high enough to elicit a therapeutic response of 131-I in vitro and in vivo. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for non-thyroidal cancers, in particular prostate cancer.
KW - Gene therapy
KW - Prostate cancer
KW - Sodium/iodide symporter (NIS)
UR - http://www.scopus.com/inward/record.url?scp=0035126384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035126384&partnerID=8YFLogxK
U2 - 10.1055/s-2001-11020
DO - 10.1055/s-2001-11020
M3 - Short survey
C2 - 11573142
AN - SCOPUS:0035126384
VL - 109
SP - 56
EP - 59
JO - Experimental and Clinical Endocrinology and Diabetes
JF - Experimental and Clinical Endocrinology and Diabetes
SN - 0947-7349
IS - 1
ER -